Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241512382 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Myrna Luna-Gutiérrez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico. Hauptthemen laut MEDLINE: Radiopharmaceuticals, B7-H1 Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Consejo Mexiquense de Ciencia y Tecnologia, “Consejo Mexiquense de Ciencia y Tecnología” (COMECyT), International Atomic Energy Agency.
Abstract (Originalsprache)
Current cancer therapies focus on reducing immunosuppression and remodeling the tumor microenvironment to inhibit metastasis, cancer progression, and therapeutic resistance. Programmed death receptor 1 (PD-1) is expressed on immune T cells and is one of the so-called checkpoint proteins that can suppress or stop the immune response. To evade the immune system, cancer cells overexpress a PD-1 inhibitor protein (PD-L1), which binds to the surface of T cells to activate signaling pathways that induce immune suppression. This research aimed to synthesize PD-L1 inhibitory peptides (PD-L1-i) labeled with lutetium-177 (177Lu-DOTA-PD-L1-i) and actinium-225 (225Ac-HEHA-PD-L1-i) and to preclinically evaluate their potential as radiopharmaceuticals for targeted radiotherapy at the tumor microenvironment level. Using PD-L1-i peptide as starting material, conjugation with HEHA-benzene-SCN and DOTA-benzene-SCN was performed to yield DOTA-PD-L1-i and HEHA-PD-L1-I, which were characterized by FT-IR, UV-vis spectroscopy, and HPLC. After labeling the conjugates with 225Ac and 177Lu, cellular uptake in HCC827 cancer cells (PD-L1 positive), conjugate specificity evaluation by immunofluorescence, radiotracer effect on cell viability, biodistribution, biokinetics, and assessment of radiation absorbed dose in mice with in duced lung micrometastases were performed. 225Ac-HEHA-PD-L1-i and 177Lu-DOTA-PD-L1-i, obtained with radiochemical purities of 95 ± 3% and 98.5 ± 0.5%, respectively, showed in vitro and in vivo specific recognition for the PD-L1 protein in lung cancer cells and high uptake in HCC287 lung micrometastases (>30% ID). The biokinetic profiles of 177Lu-DOTA-PD-L1-i and 225Ac-DOTA-PD-L1-i showed rapid blood clearance with renal and hepatobiliary elimination and no accumulation in normal tissues. 225Ac-DOTA-PD-L1-i produced a radiation dose of 5.15 mGy/MBq to lung micrometastases. In the case of 177Lu-DOTA-PD-L1-i, the radiation dose delivered to the lung micrometastases was ten times (43 mGy/MBq) that delivered to the kidneys (4.20 mGy/MBq) and fifty times that delivered to the liver (0.85 mGy/MBq). Therefore, the radiotherapeutic PD-L1-i ligands of 225Ac and 177Lu developed in this research could be combined with immunotherapy to enhance the therapeutic effect in various types of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
- Cátedras, CONACyT, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
- Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Mexico.
ORCID-Profile: Myrna Luna-Gutiérrez, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Nancy Lara-Almazán, Clara Santos-Cuevas, Erika Azorín-Vega, Blanca Ocampo-García, Guillermina Ferro-Flores
Förderung
- Consejo Mexiquense de Ciencia y Tecnologia
- “Consejo Mexiquense de Ciencia y Tecnología” (COMECyT)
- International Atomic Energy Agency
Zitieren
APA
Luna-Gutiérrez, M., Cruz-Nova, P., Jiménez-Mancilla, N., Oros-Pantoja, R., Lara-Almazán, N., Santos-Cuevas, C., Azorín-Vega, E., Ocampo-García, B., & Ferro-Flores, G. (2023). Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512382
Vancouver
Luna-Gutiérrez M, Cruz-Nova P, Jiménez-Mancilla N, Oros-Pantoja R, Lara-Almazán N, Santos-Cuevas C, et al. Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512382
BibTeX
@article{LunaGutirrez2023,
author = {Luna-Gutiérrez, Myrna and Cruz-Nova, Pedro and Jiménez-Mancilla, Nallely and Oros-Pantoja, Rigoberto and Lara-Almazán, Nancy and Santos-Cuevas, Clara and Azorín-Vega, Erika and Ocampo-García, Blanca and Ferro-Flores, Guillermina},
title = {Synthesis and Evaluation of 177Lu-DOTA-PD-L1-i and 225Ac-HEHA-PD-L1-i as Potential Radiopharmaceuticals for Tumor Microenvironment-Targeted Radiotherapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241512382}
}
EUVIMED